Physician profile
Corazon Sanchez
NPI 1922058650
$3,704.33
in general payments reported to CMS, 2019-2025
24 companies · $464 in 2025
The $464 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $289 · 2021: $596 · 2022: $608 · 2023: $809 · 2024: $696 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963 · Education: $6.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.01 |
| Education | $6.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,041.83 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $372.81 | 2020-2025 | Dyanavel Xr, Onyda Xr |
| Cranial Technologies, INC | $370.21 | 2019-2024 | Doc Band |
| Merck Sharp & Dohme LLC | $292.19 | 2019-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Ironshore Pharmaceuticals INC. | $267.03 | 2019-2024 | |
| Pfizer INC. | $239.20 | 2020-2025 | |
| Collegium Pharmaceutical, INC. | $208.53 | 2025 | Jornay Pm |
| Corium, LLC | $187.35 | 2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $146.54 | 2020-2022 | |
| Glaxosmithkline, LLC. | $97.37 | 2019-2022 | |
| Adlon Therapeutics L.P. | $85.27 | 2020-2021 | |
| Neurelis, INC. | $72.34 | 2023-2025 | Valtoco |
| Vyne Pharmaceuticals INC. | $47.94 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $46.53 | 2025 | Zoryve |
| Genentech USA, INC. | $36.94 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $33.72 | 2020-2024 | Karbinal |
| Covis Pharma Gmbh | $30.62 | 2021 | |
| Organon LLC | $26.84 | 2025 | Nexplanon |
| Sanofi Pasteur INC. | $25.11 | 2023 | |
| Shire North American Group INC | $21.74 | 2019 | |
| Kaleo, INC. | $21.38 | 2021 | |
| Seqirus USA INC | $14.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.54 | 2019 | |
| Glenmark Therapeutics INC. | $6.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corazon Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.